|
|
|
|
|
What to Expect at the European Society of Medical Oncology 2022 Annual Congress
|
|
|
|
|
|
|
| Proffered Paper Session 1: GU Tumors, Non-Prostate |
| 0415 - 0545 AM EST |
|
|
|
|
|
LBA66 - IMmotion010: Efficacy and Safety from the Phase III Study of Atezolizumab vs Placebo as Adjuvant Therapy in Patients with Renal Cell Carcinoma at Increased Risk of Recurrence After Resection
Presented By: Axel Bex, MD, Ph.D.
|
|
|
|
|
|
LBA67 - Phase III RandOmized Study Comparing PErioperative Nivolumab Versus Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network Trial
Presented By: Mohamad Allaf, MD
|
|
|
|
|
|
1735O - PD-L1 Expression on Immune Cells by SP142 Co-Localises with Dendritic Cells and Is Associated with Improved Overall Survival with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer
Presented By: Enrique G. Pulido, MD
|
|
|
|
|
|
LBA74 - Genomic Biomarkers in Peripheral Blood from Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma
Presented By: Thomas Powles MBBS, MD, MRCP
|
|
|
|
|
|
|
|
| Proffered Paper Session 1: GU Tumors, Prostate |
| 02:30 - 04:00 AM EST |
|
|
|
|
|
LBA62 - Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + AAP for Metastatic Hormone Sensitive Prostate Cancer Starting Androgen Deprivation Therapy: Overall Survival Results of 2 Randomised Phase III Trials from the STAMPEDE Protocol
Presented By: Gerhardt Attard, MD, Ph.D.
1357O - Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abi and Placebo as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
|
|
|
|
|
LBA63 - PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)
Presented By: Rahul Aggarwal, MD
|
|
|
|
|
|
| Mini Oral Session: GU Tumors, Prostate |
| 04:15 - 05:45 AM EST |
|
|
|
|
|
LBA64 - Duration of Androgen Suppression with Post-Operative Radiotherapy (DADSPORT): A Collaborative Meta-Analysis of Aggregate Data
Presented By: Sarah Burdett
|
|
|
|
|
|
LBA65 - SAKK 08/14 - IMPROVE Investigation of Metformin in Patients with Metastatic Castration-Resistant Prostate Cancer in Combination with Enzalutamide vs. Enzalutamide Alone. a Randomized, Open Label, Phase II Trial
Presented By: Christian A. Rothermundt, MD
|
|
|
|
|
|
1364MO - Preliminary Phase 2 Results of the CYPIDES Study of ODM-208 in Metastatic Castration-Resistant Prostate (mCRPC) Cancer Patients
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
|
| Mini Oral Session: GU Tumors, Non-Prostate |
| 08:45 - 10:15 AM EST |
|
|
|
|
|
LBA75 - RACE IT - a Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder (AB 65/18) – First Results
Presented By: Sebastian Schmid PD Dr. med.
|
|
|
|
|
|
| Presidential Symposium II |
| 10:30 AM - 12:05 PM EST |
|
|
|
|
|
LBA4 - Adjuvant Nivolumab plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results from the Randomized, Phase 3 CheckMate 914 Trial
Presented By: Robert Motzer, MD
|
|
|
|
|
|
|
|
1378P - Biopsy-Based Basal-Luminal Subtyping Classifier in High-Risk Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials
Presented By: Paul Nguyen, MD
1400P - Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH
Presented By: Aaron Hansen BSc, MBBS, FRACP
1421P - Effect of Abiraterone-Prednisone in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial
Presented By: Alice Bernard-Tessier, MD
|
|
|
|
|
|
|
|
|
|
1423TiP - CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Rana R. McKay, MD
|
|
|
|
|
|
|
|
| Proffered Paper Session 2: GU Tumors, Non-Prostate |
| 08:45 - 10:15 AM EST |
|
|
|
|
|
LBA68 - Bempegaldesleukin (BEMPEG) plus Nivolumab (NIVO) Compared to the Investigator’s Choice of Sunitinib or Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma: Results from a Phase 3 Randomized Study (PIVOT-09)
Presented By: Nizar Tannir, MD, FACP
|
|
|
|
|
|
LBA73 - Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Presented By: Jonathan E. Rosenberg, MD
|
|
|
|
|
|
| Mini Oral Session 2: GU Tumors, Non-Prostate |
| 10:30 AM - 12:00 PM EST |
|
|
|
|
|
LBA69 - Belzutifan, a HIF-2α Inhibitor, for Von Hippel-Lindau (VHL) Disease–Associated Neoplasms: 36 Months of Follow-up of the Phase 2 LITESPARK-004 Study
Presented By: Ramaprasad Srinivasan, MD, Ph.D.
|
|
|
|
|
|
| Presidential Symposium III |
| 10:30 AM - 12:05 PM EST |
|
|
|
|
|
LBA8 - Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of IMDC Intermediate or Poor Risk (COSMIC-313)
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
|
LBA9 - Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer: First Results of the RADICALS-HD Trial
Presented By: Chris C. Parker, MD
|
|
|
|
|
|
|
|
|
|
|
Watch Past Videos on Trials We Can Expect New Data On |
|
|
|
|
 |
|
| Long-Term Outcomes from JAVELIN Bladder 100 |
Cora Sternberg, MD, FACP
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy. |
|
|
|
|
|
|
|
|
|
| The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel |
Fred Saad, MD, FRCS
Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
 |
|
| Outcomes of the ARASENS Trial by Metastatic Subtype |
| Bertrand Tombal, MD, Ph.D. |
| In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. Tombal and Morgans acknowledge the pragmatic and effective treatment recommendations that resulted from the ARASENS trial. |
|
|
|
|
|
|
|
|
|
|
| Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial |
| Bradley McGregor, MD |
| Drs. Bradley McGregor and Rana McKay discuss an updated analysis as well as the health-related quality-of-life (HRQoL) data from the CLEAR trial. CLEAR was a large randomized Phase 3 trial comparing lenvatinib in combination with pembrolizumab versus lenvatinib with everolimus versus sunitinib. Dr. McGregor highlights the findings here in this discussion which supports lenvatinib/pembrolizumab as a first-line treatment option for advanced RCC. |
|
|
|
|
|
|
|
|
|
|
|
| Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
| Karim Fizazi, MD, Ph.D. |
| Alicia Morgans and Karim Fizazi discuss the analysis of the PEACE-1 study. The PEACE-1 study is a phase 3 trial evaluating abiraterone plus standard of care in M1 disease and local radiation therapy directed to the prostate primary. |
|
|
|
|
|
|
|
|
|
|
